Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Reviewed by: Charles Wood, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: June 19, 2005

Share article


Authors: Stupp R, Mason WP, van den Bent MJ et al
NEJM, March 10 2005;352:10, pp 987-996

Introduction

  • Glioblastoma multiforme is the most common primary malignant brain tumor in adults and carries a median survival of less than 1 year.
  • The current standard of care consists of surgical resection followed by radiotherapy.
  • Although carmustine is commonly prescribed in the United States, no randomized phase III trial of nitrosourea-based chemotherapy has demonstrated a survival benefit compared to radiation alone.
  • Temozolomide has demonstrated activity in the treatment of recurrent glioma, and a pilot phase II trial of concomitant temozolomide and radiation therapy followed by adjuvant temozolomide showed promising results.
  • The EORTC and NCIC therefore initiated a randomized, multicenter, phase III trial to compare concomitant and adjuvant temozolomide with radiation alone.

Methods

  • Eligible patients included those aged 18 to 70 years with newly diagnosed and histologically confirmed glioblastoma multiforme, and a WHO performance status of 2 or less.
  • Those patients on corticosteroids were eligible only if the dose was stable or decreasing for at least 14 days prior to randomization.
  • Study participants were stratified according to WHO performance status, whether or not they had undergone a debulking surgical procedure, and treatment center.
  • Radiation consisted of 2 Gy daily fractions (Monday through Friday) for a total dose of 60 Gy delivered to the gross tumor volume with a 2 to 3 cm margin.
  • Concomitant temozolomide was given 7 days a week at a dose of 75 mg per square meter body surface area.
  • Adjuvant temozolomide was given for 5 days, followed by a 23-day break, and then was continued for up to six cycles. The first cycle began 4 weeks after the end of radiation treatment at a dose of 150 mg per square meter body surface area; subsequent doses were increased to 200 mg per square meter body surface area, provided there were no hematologic toxic effects.
  • Tumor progression was defined as: an increase in tumor size by 25 percent, the appearance of new lesions, or an increased need for corticosteroids.
  • The primary end point was overall survival, and secondary end points were progression-free survival, safety, and quality of life
  • Analyses were conducted on an intention-to-treat basis, and the study was powered at 80 percent at a 5 percent significance level to detect a 33 percent increase in median survival.

Results

  • 573 patients from 85 institutions in 15 countries were randomized between August 2000 and March 2002
  • The median age was 56 years
  • 84 percent of patients underwent debulking surgery
  • Median follow-up was 28 months
  • Slightly more patients in the radiotherapy alone group were receiving corticosteroids at the time of randomization
  • There was a significant benefit in the temozolomide group with respect to median survival (14.6 months vs. 12.1 months), median progression-free survival (6.9 months vs. 5.0 months), and 2-year overall survival (26.5% vs. 10.4%)
  • The hazard ratio for death was 0.63 (p<0.001) and for death or disease progression was 0.54 (p<0.001) in the temozolomide group versus the radiation alone group
  • During concomitant temozolomide treatment, grade 3 or 4 neutropenia was demonstrated in 4 percent of patients, and grade 3 or 4 thrombocytopenia in 7 percent of patients
  • During adjuvant temozolomide therapy, 4 percent of patients had grade 3 or 4 neutropenia, and 11 percent had grade 3 or 4 thrombocytopenia
  • Severe infections during the radiation period occurred in 2 percent of patients in the radiotherapy alone arm and in 3 percent of patients in the temozolomide arm; severe infections during the adjuvant temozolomide period occurred in 5 percent of patients in the temozolomide arm

Author’s Conclusions

  • The addition of temozolomide chemotherapy to radiation for treatment of glioblastoma multiforme significantly prolongs survival, with a median increase of 2.5 months and a relative reduction in mortality of 37 percent.
  • There was a clinically meaningful increase (by factor of 2.5) in the 2-year survival rate among patients treated with both radiation and temozolomide.
  • The outcome for patients in the control arm compares favorably with earlier trials.

Clinical Implications

  • Concomitant and adjuvant temozolomide chemotherapy added to radiation treatment provides a statistically significant and clinically meaningful survival advantage compared to radiation alone, with a modest increase in treatment toxicity.
  • This treatment regimen represents the new standard of care in the treatment of glioblastoma multiforme.


News
Mouse study finds adding γ-secretase inhibitor to chemo can suppress tumor recurrence

Aug 26, 2010 - For glioblastoma multiforme, the most common and aggressive type of brain tumor, treatment with the chemotherapy agent temozolomide plus a γ-secretase inhibitor to suppress tumor recurrence offers a novel and promising therapeutic approach, according to a study in mice published online Aug. 24 in Cancer Research.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More